Notably, in high-risk MYCN-amplified neuroblastoma, H3K9 euchromatic histone lysine methyltransferase (EHMT) inhibitors in combination with EZH2 inhibitors exert immunomodulatory effects by inducing strong IFN-γ downstream responses [130]. Here, EZH2 is linked to neuroblastoma.